Oncolytics Provides Update on Pancreatic Cancer Program for Pelareorep, Updated Plan Follows PanCAN's Re-Evaluation Of Precision Promise Program
Portfolio Pulse from Benzinga Newsdesk
Oncolytics has updated its pancreatic cancer program for Pelareorep. The company, in collaboration with The Pancreatic Cancer Action Network (PanCAN), had initially planned to initiate a Phase 3 trial using the Precision Promise platform in H1 2024. However, Oncolytics now plans to conduct an adaptive Phase 3 program and manage it directly within its Clinical Group and a contract research organization, with the goal of enrolling the first patient in mid-2024.
November 09, 2023 | 11:35 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Oncolytics' updated plan for its pancreatic cancer program could potentially impact the company's timeline and the effectiveness of its treatment. The company now plans to conduct and manage an adaptive Phase 3 program directly, aiming to enroll the first patient in mid-2024.
The news is directly related to Oncolytics and its pancreatic cancer program. The change in plans could potentially impact the company's timeline and the effectiveness of its treatment, which could in turn affect the company's stock. However, it's unclear at this point whether the impact will be positive or negative, hence the neutral score.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100